Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.

about

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.

Item

http://www.wikidata.org/entity/Q40539487

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.

@en

type

Item

label

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.

@en

prefLabel

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.

@en

P1476

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.

@en

P2093

Hanna Jean Khoury

http://www.w3.org/2001/XMLSchema#string

Lisa M Lima

http://www.w3.org/2001/XMLSchema#string

Marian Shepard

http://www.w3.org/2001/XMLSchema#string

Martha Arellano

http://www.w3.org/2001/XMLSchema#string

Stacie Holloway

http://www.w3.org/2001/XMLSchema#string

Stephanie McMillan

http://www.w3.org/2001/XMLSchema#string

P2860

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

A renaissance for SRC

Overriding imatinib resistance with a novel ABL kinase inhibitor

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

Chronic myeloid leukemia.

P304

221-225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/JBM.S7158

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22282699

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

3262317

http://www.w3.org/2001/XMLSchema#string